Alkermes Public Limited Company (ALKS)

Alkermes' stock price has been impacted by several events in the past six months. Strong Q3 2025 earnings led to a gain in ALKS shares. The FDA granted Breakthrough Therapy designation to alixorexton, causing the stock to rise. The proposed acquisition of Avadel Pharmaceuticals is expected to contribute to revenue growth. Analyst sentiment has been largely positive, with price target adjustments. There have been instances of insider selling. BlackRock, Inc. increased its stake in Alkermes.

Information directly detailing the demand seasonality for Alkermes Plc's products and services is not explicitly available. The demand for pharmaceutical products may exhibit some stability but could also be influenced by factors such as prescription cycles, healthcare spending patterns, and new product introductions or label expansions. VIVITROL sales in Q3 2025 were driven by growth in the alcohol dependence indication market. LYBALVI sales also saw significant year-over-year growth due to increased total prescriptions. The timing of shipments ahead of holidays can also influence quarterly sales figures.

Alkermes Plc is a global biopharmaceutical company focused on developing medicines for psychiatric and neurological disorders, particularly CNS conditions. The company has a portfolio of commercial products including VIVITROL for alcohol and opioid dependence, ARISTADA and ARISTADA INITIO for schizophrenia, and LYBALVI for schizophrenia and bipolar I disorder. Alkermes also has a pipeline of clinical and preclinical candidates and offers technology platforms to third parties.

Alkermes Plc is headquartered in Dublin, Ireland, with an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Previously, Alkermes had a development and manufacturing business in Athlone, Ireland, which was sold on May 1, 2024. The company's key geographies for revenue generation include the U.S., Ireland, and the rest of the world.

Alkermes' brand reputation in the past year appears to be generally positive, driven by its focus on neuroscience and promising pipeline. The company was listed among Fortune's best places to work in 2024. Alkermes reported strong financial and operational performance in 2024. Advancements in its neuroscience pipeline, particularly alixorexton, have bolstered its reputation. The company's strategic decision to focus on its neuroscience business and explore separating its oncology business aimed to unlock value and sharpen strategic focus. Alkermes emphasizes its patient-inspired science and commitment to improving the lives of people with complex psychiatric and neurological disorders.

Alkermes Plc has significant institutional ownership, with 818 institutional owners and shareholders holding a total of 208,512,710 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Price T Rowe Associates Inc /md/, State Street Corp, Baker Bros. Advisors Lp, Renaissance Technologies Llc, American Century Companies Inc, and Geode Capital Management, Llc. Institutional ownership accounts for approximately 83.5% to 88.79% of the company, with individuals holding around 1.4%.